Reference Interval:
| Test Number
| Components
| Reference Interval
| | | Ganglioside (asialo-GM1) Antibody, IgG/IgM
| 29 IV or less: Negative
30-50 IV: Weak Positive
51-150 IV: Positive
151 IV or greater: Strong Positive
| | | Ganglioside (GM1) Antibody, IgG/IgM
| 29 IV or less: Negative
30 IV-50 IV: Weak Positive
51 IV-150 IV: Positive
151 IV or greater: Strong Positive
| | | Ganglioside (GM2) Antibody, IgG/IgM
| 29 IV or less: Negative
30 IV-50 IV: Weak Positive
51 IV-150 IV: Positive
151 IV or greater: Strong Positive
| | | Ganglioside (GD1a) Antibody, IgG/IgM
| 29 IV or less: Negative
30 IV-50 IV: Weak Positive
51 IV-150 IV: Positive
151 IV or greater: Strong Positive
| | | Ganglioside (GD1b) Antibody, IgG/IgM
| 29 IV or less: Negative
30 IV-50 IV: Weak Positive
51 IV-150 IV: Positive
151 IV or greater: Strong Positive
| | | Ganglioside (GQ1b) Antibody, IgG/IgM
| 29 IV or less: Negative
30 IV-50 IV: Weak Positive
51 IV-150 IV: Positive
151 IV or greater: Strong Positive
|
|
| Interpretive Data: |
Elevated antibody levels to ganglioside-monosialic acid (GM1), a glycolipid, have been shown in some instances to be associated with certain neurological disorders such as: lower motor neuron syndrome, amyotrophic lateral sclerosis, multiple sclerosis, other multifocal neuropathies, and systemic lupus erythematosus (SLE) with central nervous system involvement. Some normal individuals have low levels of GM1 antibodies. GM2 and GD1a antibodies have been associated with Guillain-Barre variants, motor neuropathies and sensory demyelinating neuropathy while GD1b has been associated with sensory neuropathy. GQ1b has been associated with motor and sensorimotor neuropathies, Miller-Fisher syndrome and Bickerstaff's brainstem encephalitis. The cause of such disorders is not fully understood and, therefore, the significance of elevated antibody levels has not been adequately established. The test has been designed to be an aid in the monitoring of changes in antibody levels before, during, and after treatment and may be helpful to the clinician in conjunction with other tests and clinical symptoms for the evaluation of treatment in these patients.
Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory.
|
| CPT Code(s): |
83516 Asialo GM1; 83516 GM1; 83516 GM2; 83516 GD1a, 83516 GD1b; 83516 GQ1b
|
|